Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines
dc.contributor.author | Kausar, Tasneem | en_US |
dc.contributor.author | Ahsan, Aarif | en_US |
dc.contributor.author | Hasan, Md. Raghibul | en_US |
dc.contributor.author | Lin, Lin | en_US |
dc.contributor.author | Beer, David G. | en_US |
dc.contributor.author | Ralhan, Ranju | en_US |
dc.date.accessioned | 2010-02-02T15:32:01Z | |
dc.date.available | 2011-03-01T16:26:45Z | en_US |
dc.date.issued | 2010-03-15 | en_US |
dc.identifier.citation | Kausar, Tasneem; Ahsan, Aarif; Hasan, Md. Raghibul; Lin, Lin; Beer, David G.; Ralhan, Ranju (2010). "Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines." International Journal of Cancer 126(6): 1494-1503. <http://hdl.handle.net/2027.42/64923> | en_US |
dc.identifier.issn | 0020-7136 | en_US |
dc.identifier.issn | 1097-0215 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/64923 | |
dc.description.abstract | Expression of sperm protein 17 (Sp17) mRNA has been reported in various malignancies. In an earlier study, we reported the upregulation of Sp17 transcripts in primary esophageal squamous cell carcinomas (ESCCs) using differential display and detected Sp17 transcripts in 86% of ESCCs by RT-PCR, whereas no transcripts were detected in the paired normal esophageal tissues. Herein we hypothesized that Sp17 might be used as a marker for detecting the response of anticancer therapies in ESCCs. Our results indicated that Sp17 protein levels in esophageal squamous cancer cell lines decreased in response to treatment with ( i ) the HSP90 activity inhibitor geldanamycin, ( ii ) the tyrosine kinase inhibitor erlotinib and ( iii ) cisplatin (chemotherapeutic agent commonly used in management of ESCC). In contrast, the Sp17 levels did not decrease in response to radiation therapy and treatment with the chemotherapeutic agent, gemcitabine. Further investigations showed that cisplatin induced decrease in Sp17 levels was due to transcriptional inhibition and cisplatin-resistant cell lines did not show this decrease in Sp17 levels in response to cisplatin treatment. In addition, we also carried our mass spectophotometric analysis to identify the binding partners of Sp17 to characterize its possible involvement in esophageal tumorigenesis and chemoresistance. | en_US |
dc.format.extent | 510044 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Biochemistry, All India Institute of Medical Science, New Delhi, India ; Department of Surgery, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, MI ; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Department of Biochemistry, All India Institute of Medical Science, New Delhi, India | en_US |
dc.contributor.affiliationother | Department of Biochemistry, All India Institute of Medical Science, New Delhi, India ; Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada ; Department of Otolaryngology - Head and Neck Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada ; Fax: +416-586-8628 ; Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5 | en_US |
dc.identifier.pmid | 19685492 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/64923/1/24828_ftp.pdf | |
dc.identifier.doi | 10.1002/ijc.24828 | en_US |
dc.identifier.source | International Journal of Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.